In both in vivo studies (rat BTZ-induced CIPN model and xenograft athymic nude mouse tumor model), co-administration of BTZ and suvecaltamide was tolerated with minimal weight loss followed by slight body weight gain, suggesting that combination therapy with BTZ and suvecaltamide does not lead to further weight loss. The gene discussed is CASC3; the disease is neoplasm.